David Woodhouse Email Address

Chief Executive Officer

Founded in 2008, NGM is a privately-held drug discovery company committed to the identification and development of transformational biologics for diabetes, obesity, muscle wasting and other cardiometabolic diseases. The Company is focused on discovering the next generation of therapeutics that will fundamentally change the treatment paradigm for the growing population of cardiometabolic disease patients worldwide, and NGM's core assets enable us to deliver on that promise: High-throughput platform that can discover protein and peptide hormones, as well as other druggable targets with interesting physiological activity in the gastrointestinal (GI) tract and other metabolically-relevant tissues Integrated translational research and protein sciences capabilities to enable a program to seamlessly advance from discovery to clinical development Accomplished research and management team with deep drug discovery and protein sciences experience World-class advisors with expertise in metabolic diseases, bariatric surgery science and biologics drug discovery and development NGM has identified a rich pipeline of novel targets with profound metabolic effects in various animal models of diabetes, obesity and muscle wasting.

Dr. Woodhouse became Chief Executive Officer and a member of NGM’s Board of Directors in September 2018 and has served as NGM's Chief Financial Officer since March 2015. From 2002 to 2015, he was an investment banker at Goldman Sachs & Co. LLC, most recently as a Managing Director in the healthcare investment banking group and co-head of biotechnology investment banking. Earlier in his career, Dr. Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. Dr. Woodhouse received a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine.